<DOC>
	<DOCNO>NCT02229461</DOCNO>
	<brief_summary>To determine administration naproxen sodium 220 mg maintains platelet inhibitory effect low dose Immediate Release Aspirin ( IR ASA ) regimen .</brief_summary>
	<brief_title>Naproxen Sodium/ASA Platelet Study</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Healthy , ambulatory , male female volunteer 18 70 year age Body Mass Index ( BMI ) approximately 18 30 kg/m2 , total body weight &gt; 50 kg ( 110 lb ) Female subject childbearing potential must use medically acceptable form birth control least 1 month prior screen ( 3 month oral contraceptive ) , e.g. , oral patch contraceptive , intrauterine device , DepoProveraÂ® , double barrier negative pregnancy test Screening immediately prior investigational product administration Day 1 Day 6 . Female subject nonchildbearing potential must amenorrheic least 2 year hysterectomy and/or bilateral oophorectomy Results screen clinical laboratory test within normal range consider clinically significant Principal Investigator Sponsor Be willing able participate schedule visit , treatment plan , laboratory test trial procedure accord protocol Provide personally sign date informed consent indicate subject inform pertinent aspects trial . History hypersensitivity asthma type symptom use aspirin , naproxen sodium similar pharmacological agent component product Females pregnant lactate Any disorder Aspirin Triad Syndrome ( i.e. , asthma , rhinitis nasal polyp ) , chronic urticaria Eighteen twenty year old viral infection , without fever within one month prior start Runin Period History gastrointestinal bleeding perforation , relate previous NSAID therapy . Active , history recurrent peptic ulcer/hemorrhage ( two distinct episode proven ulceration bleeding ) Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , infectious disease malignancy Any abnormal laboratory value physical find accord Investigator may interfere interpretation study result indicative underlying disease state Have take medication include NSAIDs ( except acceptable form birth control ) within 7 day prior start Runin Period throughout study , unless opinion Investigator Sponsor , medication interfere study procedure , data integrity , data interpretation compromise safety subject Have take antiplatelet anticoagulant drug within 30 day prior start Runin Period participation study Have donate blood blood component within 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>